Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guolin Zhao

Showing results (21-30 of 27) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 27 results.
Journal of Cellular Physiology|October 27, 2018
Mitochondrial dysfunction and inhibition of myoblast differentiation in mice with high-fat-diet-induced pre-diabetesDengqiu Xu, Zhenzhou Jiang, Zeren Sun, et al.
Toxicology and Applied Pharmacology|November 13, 2018
Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicityGuolin Zhao, Muhanad Elhafiz, Jingwei Jiang, et al.
Nature Medicine|October 9, 2023
Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trialRobert E MacLaren, M Dominik Fischer, James A Gow, et al.
Annals of Clinical and Translational Neurology|May 30, 2019
Neurofilament as a potential biomarker for spinal muscular atrophyBasil T Darras, Thomas O Crawford, Richard S Finkel, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase IIb Randomized Clinical Study of an Anti-α<sub>v</sub>β<sub>6</sub> Monoclonal Antibody in Idiopathic Pulmonary FibrosisGanesh Raghu, Majd Mouded, Daniel C Chambers, et al.
Expert Review of Neurotherapeutics|November 13, 2025
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophyThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
The Lancet. Neurology|August 16, 2025
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
Pageof 3

Showing results (21-30 of 27) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 27 results.
Journal of Cellular Physiology|October 27, 2018
Mitochondrial dysfunction and inhibition of myoblast differentiation in mice with high-fat-diet-induced pre-diabetesDengqiu Xu, Zhenzhou Jiang, Zeren Sun, et al.
Toxicology and Applied Pharmacology|November 13, 2018
Adaptive homeostasis of the vitamin D-vitamin D nuclear receptor axis in 8-methoxypsoralen-induced hepatotoxicityGuolin Zhao, Muhanad Elhafiz, Jingwei Jiang, et al.
Nature Medicine|October 9, 2023
Subretinal timrepigene emparvovec in adult men with choroideremia: a randomized phase 3 trialRobert E MacLaren, M Dominik Fischer, James A Gow, et al.
Annals of Clinical and Translational Neurology|May 30, 2019
Neurofilament as a potential biomarker for spinal muscular atrophyBasil T Darras, Thomas O Crawford, Richard S Finkel, et al.
American Journal of Respiratory and Critical Care Medicine|June 30, 2022
A Phase IIb Randomized Clinical Study of an Anti-α<sub>v</sub>β<sub>6</sub> Monoclonal Antibody in Idiopathic Pulmonary FibrosisGanesh Raghu, Majd Mouded, Daniel C Chambers, et al.
Expert Review of Neurotherapeutics|November 13, 2025
A plain language summary of the SAPPHIRE clinical trial of apitegromab in children and young adults with spinal muscular atrophyThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
The Lancet. Neurology|August 16, 2025
Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trialThomas O Crawford, Laurent Servais, Eugenio Mercuri, et al.
Pageof 3